


L IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

0400  
#2



In re Patent Application of

Michael S. Roberts, et al

Serial No. 10/044,955

Filed: January 15, 2002

For: TREATMENT OF NEOPLASMS WITH VIRUSES

Atty. Ref.: 2370-84

Group:

Examiner:

\* \* \* \* \*

February 19, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**


Attached is a completed Form PTO-1449 listing references in connection with this application. Copies of these references are in the file-wrapper of parent application Serial No. 09/168,883, and are therefore not being submitted with this IDS.

The Examiner is requested to initial the attached PTO-1449, and to return a copy of the initialed document to the undersigned as an indication that the listed references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT


Michael S. Roberts, et al

FILING DATE

GROUP

January 15, 2002

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,602,023	2/1997	Csatary			
	5,124,148	6/1992	Csatary et al			
	5,677,178	10/1997	McCormick			
	6,110,461	8/2000	Lee et al			
	5,215,745	6/93	CSATARY, et al			
	5,273,745	12/93	SCHIRRMACHER			
	5,585,096	12/96	MARTUZA, et al			

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
96/26285	8/1996	WO			
94/19022	9/1994	WO			X
99/18799	4/1999	WO			
99/45783	9/1999	WO			
96/34625	11/1996	WO			
00/62735	10/2000	WO			
99/08692	2/1999	WO			
94/25627	11/94	WO			
WO 93/18790	9/30/1993	PCT			
WO 86/00811	2/13/1986	PCT			
WO 86/00529	1/30/1986	PCT			
WO 99/29343	6/17/1999	PCT			
WO 99/55345	11/4/1999	PCT			
WO 00/45853	8/10/2000	PCT			
0 564 121 A2	10/6/1993	EP			
1,069,144	5/17/1967	Great Britain			
WO 99/04026	1/28/1999	PCT			
WO 99/18799	4/22/1999	PCT			
WO 97/26904	7/31/1997	PCT			
WO 96/03997	2/15/1996	PCT			
WO 95/32706	12/7/1995	PCT			
WO 89/07445	8/24/1989	PCT			
WO 97/01358	1/97	PCT			
WO 97/04805	2/97	PCT			
WO 94/18992	9/94	PCT			
JP (A) 58-116422	7/83	Japan			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Sinkovics et al, "New Developments in the Virus Therapy of Cancer: A Historical Review," Intervirology, Vol. 36, pp. 193-214 (1993).

# INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT


Michael S. Roberts, et al

FILING DATE

GROUP

January 15, 2002

(Use several sheets if necessary)



## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued...

- XP-002164069, Horvath et al, "Comparison of oncolytic Newcastle Disease Virus strains," Cancer Institute, St. Joseph's Hospital, Tampa, Florida).
- Restifo et al, "A Nonimmunogenic Sarcoma Transduced with the cDNA...", The Journal of Experimental Medicine, Vol. 175, pp. 1423-1431 (1992).
- Beattie et al, "Host-Range Restriction of Vaccinia Virus...", Virus Genes, Vol. 21, No. 1, pp. 89-94 (1996).
- Arroyo et al, "Active specific immunotherapy with vaccinia colon...", Cancer Immunol Immunother, Vol. 31, pp. 305-311 (1990).
- Yu et al, "Antiviral action of interferon- $\beta$  on ...," Med Microbial Immunol, Vol. 184, pp. 45-52 (1995).
- Nickels et al, "Identification of an amino acid change that affects...", Journal of General Virology, Vol. 75, pp. 3591-3595 (1995).
- Schubert et al, "Primary Structure of the Vesicular...", Journal of Virology, Aug. 1984, pp. 505-514.
- Balachandran et al, "Activation of the dsRNA-dependent protein...", The EMBO Journal, Vol. 17, No. 23, pp. 6888-6902 (1998).
- Durbin et al, "Targeted Disruption of the Mouse *Stat1* Gene Results...", Cell, Vol. 84, pp. 443-450 (1996).
- Stojdl et al, "Exploiting tumor-specific defects in the interferon pathway...", Nature Medicine, Vol. 6, No. 7, pp. 821-825 (2000).
- Balachandran et al, "Vesicular Stomatitis Virus...", Life, Vol. 50, pp. 135-138 (2000).
- Francoeur et al, "The Isolation of Interferon-Inducing Mutants of ...," Virology, Vol. 160, pp. 236-245 (1987).
- Database CAPLUS, on STN Columbus (OH): chemical abstract service, DN 116: 104333, CN 1054192 A, Zhang, B. "Attenuated new castle disease virus for induction of interferons to combat neoplasm or viral diseases." Abstract, 09 April 1991.
- Gresser et al. Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC19 Tumor Cells. Nature. 223 August 1969, Vol. 223, pages 844-845, see entire document.
- Rosenbergova et al, "Purification of Newcastle Disease...", Acta virol, Vol. 25, pp. 31-35 (1981).
- Maeda et al, "Isolation and Characterization of Defective Interfering...", Microbiol. Immunol., Vol. 22, No. 12, pp. 775-784 (1978).
- Strube et al, "Sensitivity of ortho- and paramyxovirus replication to human interferon  $\alpha$ ," Molec. Biol. Rep., Vol. 10, pp. 237-243 (1985).
- HASHIRO, G., et al, Archives of Virology 54, 307-315 (1977) "The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines"
- Lorence, R.M., et al, Cancer Research, 54: 6017-6021, December 1, 1994 "Complete Regression of Human Fibrosarcomaj Xenografts after Local Newcastle Disease Virus Therapy"
- Database CAPLUS, on STN Columbus (OH):chemical abstract service, DN 116: 104333, CN 1054192 A. ZHENG, B., "Attenuated new castle disease virus for induction of interferons to combat neoplasm or viral diseases," Abstract, 09 April 1991
- GRESSER, et al, "Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC19 Tumor Cells," Nature, 23 August 1969, Vol. 223, pps. 844-845
- CSATARY, L.K., et al, Orvosi Hetilap 131: 2585-2588, 1990, "Virus Vaccines For The Tratment of Cancer"
- Eck et al, "Gene-Based Therapy," Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9<sup>th</sup> Edition, chapter 5.
- Verma et al, "Gene-Based Therapy-Promises, Problems and Prospects," Nature, Vol. 389, pp. 239-242.
- Kirn, D.H., et al, MOLECULAR MEDICINE TODAY, December 1996, p. 519-527, "Replicating Viruses as Selective Cancer Therapeutics,"
- Heise, C., et al, NATURE MEDICINE, Vol. 3, No. 6, June 1997, p. 639-645 "ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents"

# INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al

FILING DATE

GROUP

January 15, 2002

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued...

- Zhang, Jian-Feng, et al, *PROC. NATL. ACAD. SCI.*, Vol. 93, pp. 4513-4518, April 1996, "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy"
- Katze, Michael G., *TRENDS IN MICROBIOLOGY*, Vol. 3, No. 2, February 1995, pp. 75-78, "Regulation of the interferon-induced PKR: can viruses cope?"
- Maheshwari, Rada K., et al, *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*, Vol. 117, No. 1, 1983, November 30, 1983, pp 161-168, "Low Infectivity of Vesicular Stomatitis Virus (VSV) Particles Released from Interferon-Treated Cells is Related to Glycoprotein Deficiency"
- Chou, Joany, et al, *PROC. NATL. ACAD. SCI. USA*, Vol. 92, pp. 10516-10520, November 1995, "Association of a Mr 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation ...herpes simplex virus 1"
- Xu, Bo, et al, *BLOOD*, Vol. 84, No. 6, September 15, 1994, pp 1942-1949, "Primary Leukemia Cells Resistant to  $\gamma$ -Interferon In Vitro are Defective in the Activation of the DNA-Binding Factor ...Factor 3"
- Petricoin III, Emanuel, et al, *MOLECULAR AND CELLULAR BIOLOGY*, Vol. 14, No. 2, Feb. 1994, pp. 1477-1486 "Human Cancer Cell Lines Express a Negative Transcriptional Regulator of the Interferon Regulatory Factor Family of DNA Binding Proteins"
- Symons, Julian A., et al, *CELL*, Vol. 81, pp. 551-560, May 19, 1995, "Vaccinia Virus Encodes a Soluble type I Interferon Receptor of Novel Structure and Broad Species Specificity"
- Linge, Claire, et al, *CANCER RESEARCH* 55, PP. 4099-4104, September 15, 1995, "Interferon System Defects in Human Malignant Melanoma"
- Machida, Haruhiko, et al, *MICROBIOL. IMMUNOL.*, Vol. 23 (7), 643-650, 1979, "Effect of Nucleosides on Interferon Production and Development of Antiviral State Induced by Poly I ! Poly C"
- Tanaka, Nobuyuki, et al, *CELL*, Vol. 77, 829-839, Jun 17, 1994, "Cellular Commitment to Oncogene-Induced Transformation or Apoptosis Is Dependent on the Transcription Factor IRF-1"
- SCIENCE*, Vol. 274, October 18, 1996, pp. 342-343, "Will a Twist of Viral Fate Lead to a New Cancer Cure?"
- Bischoff, James R., et al, *SCIENCE*, Vol. 274, October 18, 1996, pp. 373-376, "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells"
- Andreansky, Samita S., et al, *PROC. NATL. ACAD. SCI. USA*, Vol. 93, pp. 11313-11318, October 1996 Colloquium Paper, "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors"
- Gastl, Guenther, et al, *CANCER RESEARCH* 52, pp.6229-6236, November 15, 1992, "Retroviral Vector-mediated Lymphokine Gene Transfer into Human Renal ...Cells"
- Buller, R. Mark L., et al, *VIROLOGY* 164, 182-192 (1988), "Cell Proliferative Response to Vaccinia Virus Is Mediated by VGF"
- Child, Stephanie J., et al, *VIROLOGY*, 174, 625-629 (1990), "Insertional Inactivation of the large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus Is Associated with Reduced Virulence *In Vivo*"
- Restifo, Nicholas P., et al, *THE JOURNAL OF EXPERIMENTAL MEDICINE*, Vol. 175, June 1992, pp. 1423-1431, "A Nonimmunogenic Sarcoma Transduced with the cDNA for Interferon ( Elicits CD8+ T Cells against the Wild-type Tumor...Presentation Capability"
- Buller, R.M.L., et al, *NATURE*, Vol. 317, October 31, 1985, pp.813-815, "Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype"
- Haines, G.K., et al, *VIRCHOWS ARCHIV B CELL PATHOL.*, (1993) 63:289-295, "Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma"
- James, C. David, et al, *CANCER RESEARCH*, 51, pp. 1684-1688, March 15, 1991, "Chromosome 9 Deletion Mapping Reveals Interferon  $\gamma$  and Interferon  $\beta$ -1 Gene Deletions in Human Glial Tumors"

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al

FILING DATE

GROUP

January 15, 2002

(Use several sheets if necessary)

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued...

- Arroyo, Pedro J., et al, *CANCER IMMUNOL IMMUNOTHER*, (1990) 31:305-311, "Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and inteferon  $\gamma$  in a murine hepatic metastasis model"
- Zhang, Wei-Wei, et al, *CANCER GENE THERAPY*, Vol. 1, No. 1, 1994: pp. 5-13 "High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus"
- Korth, Marcus, J., et al, *GENE*, 170 (1996) 181-188, "Cloning, expression, and cellular localization of the oncogenic 58-kDa inhibitor of the RNA-activated human and mouse protein kinase"
- Barber, Glen N., et al, *PROC. NATL. ACAD. SCI. USA*, Vol. 91, pp. 4278-4282, May 1994 Biochemistry, "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties"
- Mathews, Michael B., et al, *JOURNAL OF VIROLOGY*, Vol. 65, No. 11, Nov. 1991, p. 5657-5662, "Adenovirus Virus-Associated RNA and Translation Control"
- Imani, Farhad, et al, *PROC. NATL. ACAD. SCI. USA*, Vol. 85, pp. 7887-7891, November 1988 Biochemistry, "Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype ...protein"
- Tanaka, Nobuyuki, et al, *JOURNAL OF IMMUNOTHERAPY*, Vol. 16, No. 4 (1994) pp. 283-293, "Immunotherapy of a Vaccinia Colon Oncolysate Prepared with Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon- $\gamma$  Increases the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma"
- Csatary M.D., Laszlo K., et al, *CANCER DETECTION AND PREVENTION*, 17(6):619-627 (1993), "Attenuated Veterinary Virus Vaccine for the Treatment of Cancer"
- Agent Cassel Ph.D, William A., et al, *CANCER*, Vol. 18, No. 7, pp. 863-868, July 1965, "Newcastle Disease Virus As An Antineoplastic"
- Schirmacher, V., et al, *INSTITUT FOR IMMUNOLOGIC UND GENETIK AM DEUTSCHEN KREBSFORSCHUNGSZENTRUM, 6900 HEIDELBERG, GERMANY*, pp. 19-49, March 13, 1986, "Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy"
- Lorence, Robert M., et al, *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, Vol. 80, No. 16, October 19, 1988, pp. 1305-1312, "Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- $\gamma$  and Augmentation of Its Cytotoxicity"
- Reichard, Kirk W., et al, *JOURNAL OF SURGICAL RESEARCH*, 52, 448-453 (1992), "Newcastle Disease Virus Selectively Kills Human Tumor Cells"
- Eaton, Monroe D., et al, *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, Vol. 39, No. 6, December 1967, pp. 1089-1097, "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma"
- Beverley, P.C., et al, *INT. J. CANCER*, 11, 212-223 (1973), "Immune Responses In Mice To tumour Challenge After Immunization With NewCastle Disease Virus-Infected or X-Irradiated Tumour Cells or Cell Fractions"
- Shoham, Jacob, et al, *NAT. IMMUN. CELL GROWTH REGUL.*, 1990; 9:165-172, "Augementation of Tumor Cell Immunogenicity by Viruses - An Approach to Specific Immunotherapy of Cancer"
- Bart, Robert S., et al, *NATURE NEW BIOLOGY*, Vol. 245, No. 147, October 24, 1973, pp.229-230, "Role of Interferon in the Anti-Melanoma Effects of Poly(I).Poly (C) and Newcastle Disease Virus"
- Sinkovics, Joseph, et al, *INTERVIROLOGY*, 1993, 36:193-214, "New Developments in the Virus Therapy of Cancer: A Historical Review"
- Murray, Douglas R., et al, *CANCER*, August 1977, Vol. 40, No. 2, pp. 680-686, "Viral Oncolysate in the Management of Malignant Melanoma"
- Cassel, William A., *CANCER*, 52:856-860, Sept. 1, 1983, "A Phase II Study on the Postsurgical Management of Stag Malignant Melanoma With a Newcastle Disease Virus Oncolysate"
- Cassel, William A., *MED. ONCOL. & TUMOR PHARMACOTHER.*, Vol. 9, No. 4, pp. 169-171, 1992, "A Ten-Year Follow-up on Stage II Magignant Melanoma Patients Treated Postsurgically with New Castle Disease Virus Oncolysate"

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al


FILING DATE

GROUP

January 15, 2002

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued...

- Bohle, MD, Wolfran, et al, *CANCER*, Vol. 66, No. 7, pp. 1517-1523, Oct. 1, 1990 "Postoperative Active Specific Immunization in Colorectal Cancer Patients With Virus-Modified Autologous Tumor-Cell Vaccine"
- Eaton, Monroe D., et al, *INFECTION AND IMMUNITY*, Vol. 15, No. 1, Jan. 1977, pp. 322-328, "Autoimmunity Induced by Injection of Virus-Modified Cell Membrane Antigens in Syngeneic Mice"
- Wheelock, M.D., E. Frederick, et al, *THE NEW ENGLAND JOURNAL OF MEDICINE*, Vol. 271, No. 13, Sept. 24, 1964, pp. 645-651, "Observations on the Repeated Administration of Viruses to a Patient with Acute Leukemia"
- THE LANCET*, October 9, 1971, p. 825, "Viruses in the Treatment of Cancer"
- Kenney, Shannon, et al, *JNCL EDITORIAL ISSUE 16*, June 20, 1997, pp. 1-3, June 20, 1997, "Viruses as Oncolytic Agents: a New Age for 'Therapeutic' Viruses?"
- Rodriguez, Ron, et al, *CANCER RESEARCH*, 57, 2559-2563, July 1, 1997, "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective3 Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells"
- Martuza, MD, Robert, *EXAMINER*, October 1995, Georgetown University Medical Center, pp.1-8, "Novel Treatment Approach for Malignant Brain Tumors Developed at Georgetown"
- Mineta, Toshihiro, et al, *NATURE MEDICINE*, Vol. 1, No. 9, Sept. 1995, 938-943, "Attenuated Multi-Mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas"
- Zhenxiang, Huang, et al, *ACTA ACADEMIAE MEDICINE SINICAE*, Vol. 6, No. 3, June 1984, "Studies on Viral Immunotherapy of Ascitic Tumors in Mice. -- I. Results of Treatment on Viruses of Ehrlich and S180 Ascitic Tumor Cells" p. 213-216
- Abstract, 1362, Ganly, et al, *PROCEEDINGS OF ASCO*, Vol. 16 (1997), p. 433a "Phase I Trial of Intratumoral Injection with an E1B-Attenuated Adenovirus, ONYX-015, in Patients with Recurrent p53(-) Head and Neck Cancer"
- Abstract, 1564, Kirn, et al, *PROCEEDINGS OF ASCO*, Vol. 16 (1997), p. 433a "ONYX-015, A Selectively Replicating Adenovirus, Has Antitumoral Activity Following IV Administration Alone and in Combination with Chemotherapy"
- Abstract, 1554, Izbicka, et al, *PROCEEDINGS OF ASCO*, Vol. 16 (1997), p. 433a "Effects of ONYX Adenovirus Preparations on Human Tumor Colony Forming Units"
- Abstract, 2400, Kirn, et al, *PROCEEDINGS FOR THE AMERICAN ASSOCIATION FOR CANCER RESEARCH*, Vol 37, March 1996, p. 352 "ONYX-015 Selectively Replicates in and Lyses Cells Lacking Functional Small p53."
- Field, H.J., et al, *J. HYG., CAMB.*, 81, 267-277, (1978) "The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice"
- Spriggs, Dale R., et al, *NATURE*, Vol. 297, May 6, 1982, pp 68-70, "Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants"
- Goldstein, David J., et al, *VIROLOGY*, 166, 41-51 (1988), "Factor(s) present in Herpes Simplex Virus Type 1- Infected Cells Can Compensate for the Loss of the Large Subunit of thej Viral Ribonucleotide Reductase: Characterization of an ICP6 Deletion Mutant"
- Perkus, Marion E., et al, *VIROLOGY*, 180, 406-410 (1991), "Deletion of 55 Open Reading Frames from the Termini of Vaccinia Virus"
- Meignier, Bernard, et al, *JOURNAL OF INFECTIOUS DISEASES*, 162: 313-321 (1990), "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (*Aotus trivirgatus*)"
- Hughes, Stephen J., et al, *JOURNAL OF BIOLOGICAL CHEMISTRY*, Vol. 266, No. 30, Issue of October 25, 1991, pp. 20103-20109, "Vaccinia Virus Encodes an Active Thymidylate Kinase That Complements a *cdc8* Mutant of *Saccharomyces cerevisiae*"



INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al

FILING DATE

GROUP

January 15, 2002

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued...

- Kerr, Shona M., et al, THE EMBO JOURNAL, Vol. 10, No. 13, pp. 4343-4350, (1991), "Vaccinia DNA ligase complements Saccharomyces cerevisiae cdc9, localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents"
- Clark, H. Fred, et al, JOURNAL OF INFECTIOUS DISEASES, Vol. 158, No. 3, September 1988, p. 570-587, "Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a predominantly Serotype 1 Rotavirus Season"
- Takafuji, Ernest T., et al, JOURNAL OF INFECTIOUS DISEASES, Vol. 140, No. 1, July 1979, pp.48-53, "Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4, 7, and 21 Vaccines: Safety and Immunogenicity"
- Taylor, M.W., et al, JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol. 44, No. 3, March 1970, pp. 515-519, "Virus-Induced Regression of Tumor Growth"
- Beattie, Elizabeth, et al, VIRUS GENES, 12:1, 89-94, 1996, "Host-Range Restriction of Vaccinia Virus E3L-Specific Deletion Mutants"
- Howard, Brad, et al, ANNALS NEW YORK ACADEMY OF SCIENCES, Duke University Medical Center, p. 167-187, "Retrovirus-Mediated Gene Transfer of the Human (-IFN Gene: A Therapy for Cancer"
- Suskind, R.G., et al, US Dept. of Health, Education, & Welfare, N.I.H., National Institute of Allergy and Infectious Diseases, and National Cancer Inst., Bethesda, Md. ONCOLYTIC EFFECT OF COXSACKIE VIRUS, pp. 309-318, "Viral Agents Oncolytic for Human Tumors in Heterologous Host. Oncolytic Effect of Coxsackie B. Viruses." (22932), October 29, 1956
- Bluming, Avrum Z., et al, THE LANCET, July 10, 1971, p. 105-106 "Regression of Burkitt's Lymphoma ... Association With measles Infection"
- Pasquinucci, G., THE LANCET, January 16, 1971, i, 136 "Possible Effect of Measles on Leukaemia"
- Gross, Samuel, THE LANCET, February 20, 1971, p.397-398, "Measles and Leukaemia"
- Shingu, M., JOURNAL OF GENERAL VIROLOGY (1991), 72, 2031-2034, "Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia"
- Faaberg, Kay S., et al, JOURNAL OF VIROLOGY, Vol. 62, No. 2, p. 586-593, Feb. 1988, "Strain Variation and Nuclear Association of Newcastle Disease Virus Matrix Protein"
- Holzaepfel, John H., et al, CANCER, May-June 1957, Vol. 10, pp. 577-580, "The Use of APC3 Virus As A Cancericidal Agent"
- Smith, Robert R., MD, et al, CANCER, November-December 1956, Vol. 9, pp. 1211-1218, "Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix"
- Rukavishnikova, G.E., et al, ACTA VIROL., 20:387-394, 1976, "Some Immunological Mechanisms of the Influenza Virus Antitumour Effect"
- Kalvakolanu, D.V.R., et al, PROC. NATL. ACAD. SCI. USA, Vol. 90, pp. 3167-3171, April 1993, "Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF-kB in mouse embryonal carcinoma cells"
- Foy, Teresa M., et al, J. EXP. MED. © The Rockefeller University Press - 0022-1007/93/11/1567/09, Volume 178, November 1993, pp. 1567-1575, "In Vivo CD40-gp39 Interactions are Essential for Thymus-dependent Humoral Immunity. II. Prolonged Suppression of the Humoral Immune Response by an Antibody to the Ligand for CD40, gp39"
- Blaese, R.M., et al, EUROPEAN JOURNAL OF CANCER, Vol. 30A, No. 8, pp. 1190-1193, 1994, "In situ Delivery of Suicide Genes for Cancer Treatment"
- Zhang, Jian Feng, et al, CANCER GENE THERAPY, Vol. 3, No. 1, 1996, pp. 31-38, "Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression"
- Peplinski, Gary R., et al, ANNALS OF SURGICAL ONCOLOGY, 3(2):15-23, "Prevention of Murine Breast Cancer by Vaccination with Tumor Cells Modified by Cytoline-Producing Recombinant Vaccinia Viruses"
- Cotran, Ramzi S., M.D., et al, ROBBINS PATHOLOGIC BASIS OF DISEASE, 4th Edition, p. 251, "Kinetics of Tumor Cell Growth"

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al

FILING DATE

GROUP

January 15, 2002

(Use several sheets if necessary)

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued...

Schloer, G.M., et al, JOURNAL OF VIROLOGY, Vol. 2, No. 1, Jan. 1968, pp. 40-47, "Relationship of Plaque Size and Virulence for Chickens of 14 Representative Newcastle Disease Virus Strains"

Tait, David L., et al, CLINICAL CANCER RESEARCH, Vol. 3, pp. 1959-1968, November 1997, "A Phase I Trial of Retroviral BRCA1sv Gene Therapy in Ovarian Cancer"

Martuza, Robert L., et al, SCIENCE, Vol. 252, pp. 854-855, May 10, 1991, "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant"

Hanson, R.P., et al, SCIENCE, Vol. 122, pp. 156-157, July 22, 1955, "Identification of Vaccine Strains of Newcastle Disease Virus"

Chambers, Renee, et al, PROC. NATL. ACAD. SCI. USA, Vol. 92, pp. 1411-1415, February 1995, "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma"

Asada, Teruo, MD, CANCER, Vol. 34, pp. 1907-1928, December 1974, "Treatment of Human Cancer with Mumps Virus"

Sreevalsan, Thazepadath, BIOLOGIC THERAPY OF CANCER: PRINCIPLES AND PRACTICE, pp. 347-364, Chapter 14 Biologic Therapy with Interferon- $\alpha$  and  $\beta$ : Preclinical Studies

Stoner, Gary D., et al, NATURE, Vol. 245, October 12, 1973, pp. 319-320, "Effect of Neuraminidase pretreatment on the Susceptibility of Normal and Transformed Mammalian Cells to Bovine Enterovirus 261"

Joklik, W.K., VIROLOGY, Second Edition 1990, pp. 383-410, "Interferons"

Schnell, Matthias, J., et al, CELL, Vol. 90, pp. 849-857, September 5, 1997, "Construction of a Novel Virus that Targets HIV-1-Infected Cells and Controls HIV-1 Infection"

Lorence, Robert M., et al, JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol. 86, No. 16, August 17, 1994, pp. 1228-1233, "Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy"

Kirchner, H.H., et al, WORLD J UROL. (1995) 13:171-173, "Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines"

Murphy, Frederick A., et al, VIROLOGY, Second Edition, 1990, Chapter 2, pp. 9-35, "Virus Taxonomy"

Csatary, Laszlo K., THE LANCET, October 9, 1971, p. 825, "Viruses in the Treatment of Cancer"

Ahlert, T., et al, CANCER RES. 50 (1990), pp. 5962-5968, "Isolation of a Human Melanoma Adapted Newcastle Disease Virus Mutant with Highly Selective Replication Patterns"

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)